Sterling Capital Management LLC Sells 4,326 Shares of IQVIA Holdings Inc. $IQV

Sterling Capital Management LLC lessened its position in shares of IQVIA Holdings Inc. (NYSE:IQV) by 43.2% in the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 5,689 shares of the medical research company’s stock after selling 4,326 shares during the period. Sterling Capital Management LLC’s holdings in IQVIA were worth $970,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also modified their holdings of IQV. Ameliora Wealth Management Ltd. acquired a new position in shares of IQVIA during the 4th quarter worth approximately $25,000. International Assets Investment Management LLC acquired a new stake in IQVIA in the fourth quarter valued at about $27,000. Gilpin Wealth Management LLC bought a new stake in shares of IQVIA during the 4th quarter valued at approximately $27,000. CrossGen Wealth LLC bought a new stake in shares of IQVIA during the fourth quarter worth $28,000. Finally, Measured Wealth Private Client Group LLC acquired a new position in IQVIA in the 3rd quarter worth about $30,000. 89.62% of the stock is currently owned by institutional investors and hedge funds.

IQVIA Price Performance

Shares of NYSE:IQV opened at $193.53 on Wednesday. IQVIA Holdings Inc. has a fifty-two week low of $154.50 and a fifty-two week high of $247.04. The company’s 50-day moving average is $175.19 and its 200 day moving average is $189.44. The company has a market capitalization of $32.30 billion, a P/E ratio of 23.98, a price-to-earnings-growth ratio of 1.66 and a beta of 1.21. The company has a debt-to-equity ratio of 2.20, a quick ratio of 0.75 and a current ratio of 0.75.

IQVIA (NYSE:IQV) last issued its quarterly earnings results on Tuesday, May 5th. The medical research company reported $2.90 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.83 by $0.07. IQVIA had a net margin of 8.33% and a return on equity of 30.50%. The company had revenue of $4.15 billion during the quarter, compared to analyst estimates of $4.10 billion. During the same quarter last year, the business posted $2.70 EPS. IQVIA’s quarterly revenue was up 8.4% compared to the same quarter last year. IQVIA has set its FY 2026 guidance at 12.650-12.950 EPS. On average, equities research analysts forecast that IQVIA Holdings Inc. will post 11.6 earnings per share for the current year.

IQVIA declared that its Board of Directors has authorized a stock buyback plan on Thursday, May 7th that authorizes the company to repurchase $2.00 billion in shares. This repurchase authorization authorizes the medical research company to repurchase up to 6.8% of its stock through open market purchases. Stock repurchase plans are typically an indication that the company’s board believes its shares are undervalued.

Wall Street Analysts Forecast Growth

A number of equities research analysts have weighed in on IQV shares. Morgan Stanley reissued an “equal weight” rating and set a $200.00 target price (down from $225.00) on shares of IQVIA in a report on Wednesday, June 17th. TD Cowen raised IQVIA from a “hold” rating to a “buy” rating and lifted their price objective for the stock from $174.00 to $213.00 in a research report on Monday, March 9th. Wall Street Zen downgraded shares of IQVIA from a “buy” rating to a “hold” rating in a research report on Saturday. Evercore restated an “outperform” rating and set a $185.00 price objective on shares of IQVIA in a report on Wednesday, April 8th. Finally, Barclays raised shares of IQVIA from an “equal weight” rating to an “overweight” rating and set a $210.00 price objective on the stock in a research note on Friday, March 6th. Two research analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and three have issued a Hold rating to the company. According to MarketBeat.com, IQVIA presently has an average rating of “Moderate Buy” and a consensus target price of $222.56.

About IQVIA

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.